

Eibhlin A Conneally

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6164023/publications.pdf>

Version: 2024-02-01

93
papers

3,308
citations

186265

28
h-index

149698

56
g-index

94
all docs

94
docs citations

94
times ranked

3143
citing authors

#	ARTICLE	IF	CITATIONS
1	Expansion <i>in vitro</i> of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabeticâ€” <i>scid/scid</i> mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 9836-9841.	7.1	449
2	Cytokine manipulation of primitive human hematopoietic cell self-renewal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 4698-4703.	7.1	278
3	Guideline for investigation and management of adults and children presenting with a thrombocytosis. <i>British Journal of Haematology</i> , 2010, 149, 352-375.	2.5	253
4	Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. <i>Leukemia</i> , 2017, 31, 1525-1531.	7.2	232
5	Hematopoietic stem cells: Inferences from <i>in vivo</i> assays. <i>Stem Cells</i> , 1997, 15, 1-5.	3.2	183
6	Efficient Retroviral-Mediated Gene Transfer to Human Cord Blood Stem Cells With <i>In Vivo</i> Repopulating Potential. <i>Blood</i> , 1998, 91, 3487-3493.	1.4	156
7	Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 945-954.	2.5	124
8	Optimization of retroviral-mediated gene transfer to human NOD/SCID mouse repopulating cord blood cells through a systematic analysis of protocol variables. <i>Experimental Hematology</i> , 1999, 27, 817-825.	0.4	101
9	Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. <i>British Journal of Haematology</i> , 2007, 138, 821-822.	2.5	99
10	Ontogeny-associated changes in the cytokine responses of primitive human haemopoietic cells. <i>British Journal of Haematology</i> , 1998, 101, 770-778.	2.5	95
11	Quantitation of the quiescent fraction of long-term culture-initiating cells in normal human blood and marrow and the kinetics of their growth factor-stimulated entry into S-phase <i>in vitro</i> . <i>Blood</i> , 1995, 86, 3314-3321.	1.4	92
12	Guideline for the diagnosis and management of myelofibrosis. <i>British Journal of Haematology</i> , 2012, 158, 453-471.	2.5	89
13	Rapid and efficient selection of human hematopoietic cells expressing murine heat-stable antigen as an indicator of retroviral-mediated gene transfer. <i>Blood</i> , 1996, 87, 456-464.	1.4	78
14	Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2005, 36, 825-830.	2.4	76
15	Combined real-time PCR and galactomannan surveillance improves diagnosis of invasive aspergillosis in high risk patients with haematological malignancies. <i>British Journal of Haematology</i> , 2013, 161, 517-524.	2.5	61
16	Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease with Rabbit Antithymocyte Globulin. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000, 9, 367-374.	1.8	60
17	Chimaerism following allogeneic bone marrow transplantation: detection of residual host cells using the polymerase chain reaction. <i>British Journal of Haematology</i> , 1989, 73, 205-210.	2.5	58
18	Acute Myelogenous Leukemia with t(8;21)â€”Identification of a Specific Immunophenotype. <i>Leukemia and Lymphoma</i> , 2003, 44, 1713-1718.	1.3	46

#	ARTICLE	IF	CITATIONS
19	Modulation of p210BCR-ABL activity in transduced primary human hematopoietic cells controls lineage programming. <i>Blood</i> , 2002, 99, 3197-3204.	1.4	44
20	Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. <i>Leukemia</i> , 2021, 35, 1344-1355.	7.2	43
21	Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. <i>Leukemia Research</i> , 2018, 64, 34-41.	0.8	41
22	Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. <i>British Journal of Haematology</i> , 2014, 167, 421-423.	2.5	40
23	Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. <i>British Journal of Haematology</i> , 2014, 167, 418-420.	2.5	37
24	Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF). <i>Blood</i> , 2015, 126, 4060-4060.	1.4	32
25	Large granular lymphocyte leukemia: natural history and response to treatment. <i>Leukemia and Lymphoma</i> , 2010, 51, 839-845.	1.3	31
26	Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 435-443.	2.0	30
27	Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2014, 166, 800-802.	2.5	30
28	CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 2371-2379.	1.3	28
29	The Vascular Targeting Agent Combretastatin-A4 and a Novel cis-Restricted β -Lactam Analogue, CA-432, Induce Apoptosis in Human Chronic Myeloid Leukemia Cells and Ex Vivo Patient Samples Including Those Displaying Multidrug Resistance. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 302-313.	2.5	26
30	Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo. <i>British Journal of Cancer</i> , 2010, 102, 1474-1482.	6.4	22
31	A new human plasma cell line, Karpas 620, with translocations involving chromosomes 1, 11 and 14. <i>British Journal of Haematology</i> , 1990, 74, 70-76.	2.5	20
32	Correlation of the BRAF V600E mutation in hairy cell leukaemia with morphology, cytochemistry and immunophenotype. <i>International Journal of Laboratory Hematology</i> , 2012, 34, 417-421.	1.3	20
33	The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT. <i>Bone Marrow Transplantation</i> , 2014, 49, 843-844.	2.4	20
34	Targeted next-generation sequencing of familial platelet disorder with predisposition to acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 175, 161-163.	2.5	18
35	Bone marrow transplantation for adults with acute leukaemia and 11q23 chromosomal abnormalities. <i>British Journal of Haematology</i> , 1998, 103, 630-638.	2.5	15
36	Δ CBF β deletion associated with inv(16) in acute myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2005, 162, 122-126.	1.0	15

#	ARTICLE	IF	CITATIONS
37	Autoimmune Hemolytic Anemia Associated With Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4993-4995.	1.6	15
38	Adenomatoid tumor of the testis in a patient on imatinib therapy for chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 1394-1396.	1.3	14
39	<scp>BK</scp> virus (<scp>BKV</scp>) plasma dynamics in patients with <scp>BKV</scp>â€associated hemorrhagic cystitis following allogeneic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2013, 15, 276-282.	1.7	14
40	Proteomic Profiling of Serological Responses to <i>Aspergillus fumigatus</i> Antigens in Patients with Invasive Aspergillosis. <i>Journal of Proteome Research</i> , 2016, 15, 1580-1591.	3.7	13
41	Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance?. <i>British Journal of Haematology</i> , 2004, 127, 367-369.	2.5	12
42	Molecular response to first line nilotinib in a patient with e19a2 BCRâ€ABL1 chronic myeloid leukemia. <i>Leukemia Research</i> , 2011, 35, e169-e170.	0.8	12
43	Nilotinib 300 mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response. <i>Leukemia Research</i> , 2014, 38, 310-315.	0.8	12
44	Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis. <i>Clinical and Translational Oncology</i> , 2018, 20, 420-423.	2.4	12
45	Nilotinib and allogeneic stem cell transplantation in a chronic myeloid leukemia patient with e6a2 and e1a2 BCR-ABL transcripts. <i>Leukemia Research</i> , 2010, 34, e204-e205.	0.8	11
46	T-lymphoblastic leukemia/lymphoma: a single center retrospective study of outcome. <i>Leukemia and Lymphoma</i> , 2010, 51, 1035-1039.	1.3	8
47	Identification of <i>MPL</i> W515L/K Mutations in Patients with Primary Myelofibrosis and Essential Thrombocythaemia by Allele-Specific Polymerase Chain Reaction. <i>Acta Haematologica</i> , 2009, 121, 221-222.	1.4	7
48	Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, e29-31.	2.3	7
49	Use of DLI to achieve complete donor chimerism in a patient receiving systemic immunosuppression for refractory AIHA post-NST. <i>Bone Marrow Transplantation</i> , 2005, 36, 735-736.	2.4	6
50	Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. <i>Irish Journal of Medical Science</i> , 2007, 176, 105-109.	1.5	6
51	Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation. <i>Haematologica</i> , 2009, 94, 296-298.	3.5	6
52	Diagnostic pathway for the investigation of thrombocytosis. <i>British Journal of Haematology</i> , 2013, 161, 604-606.	2.5	6
53	Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms. <i>Genetic Testing and Molecular Biomarkers</i> , 2018, 22, 98-103.	0.7	6
54	Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR.. <i>Blood</i> , 2010, 116, 3427-3427.	1.4	6

#	ARTICLE	IF	CITATIONS
55	Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis. <i>Blood</i> , 2014, 124, 711-711.	1.4	6
56	Allografting for indolent lymphoid neoplasms. <i>Annals of Oncology</i> , 2000, 11, S59-S61.	1.2	5
57	Retinal and cerebral toxoplasmosis following nonmyeloablative stem cell transplant for chronic lymphocytic leukaemia. <i>Bone Marrow Transplantation</i> , 2005, 36, 1019-1020.	2.4	5
58	Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.. <i>Blood</i> , 2009, 114, 3294-3294.	1.4	5
59	Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: Results from the ENESTFreedom study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7001-7001.	1.6	5
60	Restoration of donor chimerism by nilotinib in a chronic myeloid leukaemia patient post mutation-associated imatinib mesylate resistance and allogeneic stem cell transplant failure. <i>Bone Marrow Transplantation</i> , 2008, 42, 833-835.	2.4	4
61	5q - syndrome: complete response to chemotherapy. <i>International Journal of Laboratory Hematology</i> , 1990, 12, 101-103.	0.2	4
62	Monitoring Residual Disease in the Ph-Negative Myeloproliferative Neoplasms Post-Allogeneic Stem Cell Transplantation: More Mutations and More Methodologies. <i>Frontiers in Oncology</i> , 2014, 4, 212.	2.8	4
63	Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations. <i>Familial Cancer</i> , 2014, 13, 659-663.	1.9	4
64	Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTFreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase. <i>Blood</i> , 2016, 128, 3066-3066.	1.4	4
65	Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 192-week data from the ENESTFreedom study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7013-7013.	1.6	4
66	Isolation and analysis of different subpopulations of normal human breast epithelial cells early after their infection with a retroviral vector encoding a cell surface marker. <i>Breast Cancer Research and Treatment</i> , 1997, 44, 153-165.	2.5	3
67	Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia. <i>Irish Journal of Medical Science</i> , 2009, 178, 441-446.	1.5	3
68	BCR-ABL1 Kinase Domain Mutation Analysis in an Irish Cohort of Chronic Myeloid Leukemia Patients. <i>Genetic Testing and Molecular Biomarkers</i> , 2013, 17, 170-173.	0.7	3
69	Burkitt leukaemia/lymphoma: R-CODOX-M/R-IVAC remains gold standard treatment in BL. <i>Irish Journal of Medical Science</i> , 2016, 185, 773-777.	1.5	3
70	Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 85-88.	0.9	3
71	An acquired <i>NRAS</i> mutation contributes to neutrophilic progression in a patient with primary myelofibrosis. <i>British Journal of Haematology</i> , 2018, 183, 308-310.	2.5	3
72	Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (>=65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR4.5: Results from ENESTFreedom. <i>Blood</i> , 2020, 136, 7-8.	1.4	3

#	ARTICLE	IF	CITATIONS
73	A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.. Journal of Clinical Oncology, 2014, 32, 7022-7022.	1.6	3
74	Autologous stem cell transplantation in myeloma: the St James's Hospital experience, 1997-2003. Irish Journal of Medical Science, 2005, 174, 26-32.	1.5	2
75	Incidence and significance of FLT3-ITD and NPM1 mutations in patients with normal karyotype acute myeloid leukaemia. Irish Journal of Medical Science, 2010, 179, 507-510.	1.5	2
76	Chronic myeloid leukaemia presenting post-radiotherapy for prostate cancer: further evidence for an immunosurveillance effect. British Journal of Haematology, 2013, 162, 708-710.	2.5	2
77	Chronic Myeloid Leukemia with an e6a2BCR-ABL1Fusion Transcript: Cooperating Mutations at Blast Crisis and Molecular Monitoring. Case Reports in Hematology, 2017, 2017, 1-5.	0.4	2
78	Can absolute basophilia distinguish e1a2 BCR-ABL1 chronic myeloid leukemia from chronic myelomonocytic leukemia?. Blood Cells, Molecules, and Diseases, 2021, 87, 102521.	1.4	2
79	Treatment of Lymphoid Malignancies with Non-myeloablative Stem Cell Transplantation. Hematology, 2002, 7, 151-155.	1.5	1
80	Marrow aplasia developing 13 years after HLA-identical sibling allogeneic transplantation for chronic myeloid leukaemia: successful treatment with antithymocyte globulin and peripheral blood stem cell infusion from the original donor. European Journal of Haematology, 2006, 76, 258-260.	2.2	1
81	Risk Factors for BK Virus-Associated Hemorrhagic Cystitis in Allogeneic Stem Cell Transplant Recipients. Infectious Diseases in Clinical Practice, 2013, 21, 168-171.	0.3	1
82	Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation. Case Reports in Hematology, 2015, 2015, 1-4.	0.4	1
83	Capricious CALR mutated clones in myeloproliferative neoplasms. Blood Cells, Molecules, and Diseases, 2016, 57, 110-111.	1.4	1
84	Transformed follicular lymphoma (tFL): consolidation therapy may improve survival. Irish Journal of Medical Science, 2017, 186, 589-595.	1.5	1
85	Myeloid sarcoma: deciphering a rare cause of cardiac compromise. British Journal of Haematology, 2019, 186, 203.	2.5	1
86	FIP1L1-CPDGFR± p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-CPDGFR± Positive Leukemia. HemaSphere, 2019, 3, e182.	2.7	1
87	Long-term treatment-free remission (TFR) following frontline (1L) nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom 144-wk results.. Journal of Clinical Oncology, 2018, 36, 7063-7063.	1.6	1
88	Royal academy of medicine in ireland section of pathology. Irish Journal of Medical Science, 1989, 158, 310-313.	1.5	0
89	Changes in the cytokine regulation of stem cell self-renewal during ontogeny. Stem Cells, 2009, 16, 177-184.	3.2	0
90	CALR mutation profile in Irish patients with myeloproliferative neoplasms. Hematology/ Oncology and Stem Cell Therapy, 2016, 9, 112-115.	0.9	0

#	ARTICLE	IF	CITATIONS
91	A single-centre analysis of 30 patients with relapsed germ cell tumours treated with the TI-CE regimen. Bone Marrow Transplantation, 2016, 51, 856-859.	2.4	0
92	Myelodysplastic Syndrome/Acute Myeloid Leukemia Arising in Idiopathic Erythrocytosis. Case Reports in Hematology, 2018, 2018, 1-4.	0.4	0
93	Molecular responses in e19a2 BCR-ABL1 chronic myeloid leukemia. Leukemia Research Reports, 2020, 13, 100195.	0.4	0